BioSpace News Archive

Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced the first patient has been dosed in an open-label study of SNX-5422 added to ibrutinib.

Lycera today announced the initiation of the Phase 2a portion of the company’s Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a first-in-class oral, selective retinoic acid-related orphan receptor-gamma (RORgamma) agonist, designed to reprogram the immune system in patients with advanced, relapsed or refractory solid tumors.

AOBiome today announced positive efficacy and safety findings from the Phase 2b clinical trial of the Company’s Ammonia Oxidizing Bacteria (AOB) product candidate for the treatment of mild-to-moderate acne vulgaris.

Servier CDMO today announced that the company has invested &7.5M in intensified technology including continuous chromatography with SMB and SFC with solvent recycling of up to 90% to lower environmental impact.

Tetra Bio-Pharma Inc., a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Derek Herrera, the founder of Spinal Singularity, announced the closing of an equity investment in the amount of $3.1M.

CRH Medical plans to release its unaudited results for the quarter ended September 30, 2017, on Wednesday, November 1, 2017 after market close.

Imprimis today announced it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable and potentially lower-cost alternatives to Restasis.

Accuray announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy System by University Hospital of Tours (CHU).

NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.